Introducing The Trust Revolution: A New Tech Podcast Show

MarketScale is adding another exciting original podcast to the lineup of thought-leading shows, as WhiteFox CEO Luke Fox is set to host The Trust Revolution, a show aimed at exploring how innovations in business and technology are redefining who, what and how we trust.

As our lives become ever more connected, globalized and intrinsically linked, there is a revolution brewing to ensure we can step forward confidently to embrace the world we find ourselves in. Bringing together leaders, lawmakers and lawbreakers, The Trust Revolution dissects how trust is established, shared and challenged as we enter the next great technological revolution.

WhiteFox is a global leader in drone airspace security. Pioneering the safe integration of drones into society, WhiteFox products securely manage drones in sensitive airspace worldwide.

Prior to WhiteFox, Fox successfully built and operated cyber-forensics and high-performance drone manufacturing companies. During this time, he came to recognize the power that drones have to change the world—it just depends whose hands they are in. This realization spurred his vision for establishing a comprehensive market solution to ensure drones fly safely and legally.

Outside of WhiteFox, Fox is a strong, persistent advocate for children’s rights and legislative reform and is actively involved in the technology community on the central coast of California, where he lives and works. He was named to Forbes 30 Under 30 list for his ongoing innovation and advocacy.

With The Trust Revolution, he’ll explore how security and counter operations are built into technology and the emerging security standards the industry can expect as new technologies emerge. With great power comes great responsibility.

Stay tuned for the debut episode of The Trust Revolution on November 3rd, then catch future episodes every other Tuesday.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More